Emerging experience with meningococcal serogroup B protein vaccines. (4th May 2017)

• Record Type: Journal Article
• Authors: Toneatto, Daniela; Pizza, Mariagrazia; Masignani, Vega; Rappuoli, Rino
• Is Part Of: Expert review of vaccines. Volume 16:Number 5(2017)
• Page Start: 433
• Page End: 451
• Publication Date: 2017-05-04
• Subjects: 4CMenB -- carriage -- immunogenicity -- MATS -- MEASURE -- meningococcal serogroup B -- Neisseria meningitidis -- reverse vaccinology -- rLP2086 -- strain coverage; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2017.1308828
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Introduction : The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered : Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary : The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials. Continuing uncertainties exist around the appropriate age groups to be immunized, the degree and duration of efficacy, and the impact on nasopharyngeal carriage which has implications for strategies to interrupt transmission and maximize herd protection effects. Universal vaccination programs such as those undertaken in Quebec and the United Kingdom are providing important information on these issues. The potential for MenB vaccines to prevent infection by other serogroups appears promising, and the impact of MenB vaccines on other pathogenic neisserial species with similar surface proteins warrants further investigation.